24/7 Market News Snapshot 21 August, 2024 – ANEW MEDICAL, INC. Common Stock (NASDAQ:WENA)
DENVER, Colo., 21 August, 2024 (247marketnews.com) – (Nasdaq:WENA) are discussed in this article.
Anew Medical, Inc. (Nasdaq:WENA) is navigating a challenging market environment, with pre-market trading reflecting no change from the previous session at $1.258, following a notable drop in the last close to $1.030. This bearish trend may signal volatility, prompting investors to exercise caution. The trading volume has reached 1.32 million shares, indicating a heightened interest that may be driven by recent developments in the healthcare sector. Key price levels are crucial for traders to monitor; a decline below $1.030 could suggest a deeper downturn, while resistance can potentially be found around $1.300.
In a significant strategic development, Anew Medical has announced an exclusive worldwide license agreement with Transfertech Sherbrooke (TTS) for its groundbreaking Nanoject technology. This innovative needle-free, freeze-dried nanopowder autoinjector presents a modern solution to the prevalent challenges of needle phobia and injection anxiety experienced by millions. The Nanoject device employs a high-speed pressure-driven flow to deliver medications directly through the skin at a remarkable velocity of 600 meters per second. This technique allows for both intradermal and subcutaneous administration, enhancing the storage potential and stability of drugs compared to traditional solutions.
Dr. Joseph Sinkule, CEO and Founder of Anew, emphasized the company’s commitment to developing pioneering medical technologies to meet critical healthcare demands. He highlighted that the Nanoject technology not only aligns with their innovative spirit but also opens new revenue pathways, bolstering ongoing efforts in gene therapy. With backing from the esteemed Université de Sherbrooke and robust patent protections, Anew is well-prepared to advance this transformative device into the marketplace, aiming to improve the quality of life for patients with chronic conditions and reaffirm its position in the rapidly evolving medical landscape.